Shares of Citius Oncology, Inc. (NASDAQ:CTOR - Get Free Report) shot up 1.9% during mid-day trading on Friday . The stock traded as high as $5.89 and last traded at $5.32. 647,470 shares traded hands during trading, a decline of 48% from the average session volume of 1,254,936 shares. The stock had previously closed at $5.22.
Wall Street Analysts Forecast Growth
Several brokerages have issued reports on CTOR. Maxim Group lowered Citius Oncology from a "strong-buy" rating to a "hold" rating in a report on Friday, May 23rd. Citigroup lowered Citius Oncology to a "hold" rating in a report on Friday, May 23rd.
Check Out Our Latest Research Report on CTOR
Citius Oncology Stock Performance
The company has a current ratio of 0.36, a quick ratio of 0.05 and a debt-to-equity ratio of 0.11. The stock has a fifty day moving average of $1.82 and a 200-day moving average of $1.27.
Citius Oncology (NASDAQ:CTOR - Get Free Report) last released its quarterly earnings results on Wednesday, May 14th. The company reported ($0.11) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.09) by ($0.02).
Institutional Investors Weigh In On Citius Oncology
A hedge fund recently bought a new stake in Citius Oncology stock. Citadel Advisors LLC acquired a new stake in Citius Oncology, Inc. (NASDAQ:CTOR - Free Report) during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund acquired 22,699 shares of the company's stock, valued at approximately $26,000. 70.52% of the stock is owned by institutional investors and hedge funds.
About Citius Oncology
(
Get Free Report)
Citius Oncology, Inc is a pharmaceutical company, which engages in developing and commercializing targeted oncology therapies. Its lead product candidate is LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein, for the treatment of patients with persistent or recurrent CTCL, a rare form of non-Hodgkin lymphoma.
See Also
Before you consider Citius Oncology, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Citius Oncology wasn't on the list.
While Citius Oncology currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
